Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption

New Zealand Medical Journal

Volumn 122, Issue 1300, 2009, Pages 64-71

  Graudins, Andis ^a,b   Pham, Hanh Ngoc ^a   Salonikas, Chris ^a   Naidoo, Daya ^a   Chan, Betty ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED CARBON; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYSTEINE; GLUCURONIDE; INDAPAMIDE; MIRTAZAPINE; PANADOL OSTEO; PARACETAMOL; PERINDOPRIL; SULFATE; UNCLASSIFIED DRUG; VERAPAMIL;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; CASE REPORT; CONTROLLED DRUG RELEASE; DEPRESSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG OVERDOSE; EARLY INTERVENTION; FEMALE; GLASGOW COMA SCALE; HUMAN; HYPERTENSION; LIVER TOXICITY; REPEATED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ACETAMINOPHEN; ACETYLCYSTEINE; AGED; ALANINE TRANSAMINASE; ANALGESICS, NON-NARCOTIC; ASPARTATE AMINOTRANSFERASES; DELAYED-ACTION PREPARATIONS; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; INFUSIONS, INTRAVENOUS; OVERDOSE;

EID: 70049102137     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Anonymous. Panadol Extend Product Information (GlaxoSmithKline Consumer Healthcare).
2. Tan C, Graudins A. Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. Emerg Med Australas 2006;18(4):398-403.
3. Graudins A, Chiew A, Chan BS. Overdose with modified-release paracetamol results in delayed and prolonged absorption of paracetamol: A case series. Internal Medicine Journal 2009;In press.
4. Roberts DM, Buckley NA. Prolonged absorption and delayed peak paracetamol concentration following poisoning with extended-release formulation. Med J Aust 2008;188(5):310-1.
5. Watson WA, Vraa EP, Neau SH. Dissolution of acetaminophen tablets under overdose conditions. Ann Pharmacother 1997;31(10):1261-3.
6. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999;37(6):753-7.
7. Cetaruk EW, Dart RC, Hurlbut KM, et al. Tylenol Extended Relief overdose. Ann Emerg Med 1997;30(1):104-8.
8. Bizovi KE, Aks SE, Paloucek F, et al. Late increase in acetaminophen concentration after overdose of Tylenol Extended Relief. Ann Emerg Med 1996;28(5):549-51.
9. Chan BS, Graudins A, Chiew A. Acetaminophen Poisoning with a Difference. (Abstract). Clin Toxicol 2008;48(7):601-2.
10. Smith SW, Howland MA, Hoffman RS, Nelson LS. Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of N-acetylcysteine therapy. Ann Pharmacother 2008;42(9):1333-9.
11. Daly FFS, Fountain J, Graudins A, et al. Consensus Statement: New Guidelines for the Management of Paracetamol (Acetaminophen) Poisoning in Australia and New Zealand - Explanation and Elaboration. Med J Aust 2008;188(1):296-301.
12. Gelotte CK, Auiler JF, Lynch JM, et al. Disposition of acetaminophen at 4, 6, and 8g/day for 3 days in healthy young adults. Clin Pharmacol Ther 2007;81(6):840-8.